Active Biotech AB's Partner Teva Pharmaceutical Industries Limited Initiates a Further Clinical Trial in Multiple Sclerosis
Published: Nov 04, 2013
Lund, Sweden, November 4, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its partner Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will initiate a further clinical trial, LIBRETTO, to evaluate the efficacy, safety and tolerability of two doses of oral laquinimod (0.6 and 1.2 mg/day), compared to interferon beta-1a, in patients with relapsing remitting multiple sclerosis. Primary endpoint of the study will be brain atrophy. For further details please see www.clinicaltrials.gov where the trial will appear during this week.
Help employers find you! Check out all the jobs and post your resume.